DCC-2036

Deciphera Pharmaceuticals, LLC · Phase 1 active Small molecule

At a glance

Generic name	DCC-2036
Also known as	rebastinib
Sponsor	Deciphera Pharmaceuticals, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DCC-2036 CI brief — competitive landscape report
DCC-2036 updates RSS · CI watch RSS
Deciphera Pharmaceuticals, LLC portfolio CI